Literature DB >> 1718222

Progressive renal toxicity due to ifosfamide.

D Heney1, J Wheeldon, P Rushworth, C Chapman, I J Lewis, C C Bailey.   

Abstract

A prospective and follow up study of renal tubular and glomerular function in 11 children receiving ifosfamide treatment was conducted. Each child received between four and 14 courses of ifosfamide, given as a continuous infusion of 3 g/m2 over 24 hours for two or three days. Evidence of renal toxicity was seen in all patients. There was a treatment related rise in urinary tubular markers (N-acetyl-glucosaminidase and alpha 1 microglobulin). Recovery was limited, so that by the fourth course of treatment all values remained abnormal. There was an associated treatment related reduction in plasma phosphate concentration. Urinary albumin also showed a treatment related rise, but with fewer abnormal values. Electrophoresis was used to confirm tubular or glomerular patterns. Glomerular toxicity was less severe and occurred in fewer patients. The follow up study showed persistence of tubular damage in all seven patients examined, and there was evidence of glomerular damage in five of the seven children. Children receiving ifosfamide need to be carefully monitored for renal toxicity both during treatment and at follow up.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718222      PMCID: PMC1793427          DOI: 10.1136/adc.66.8.966

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  13 in total

Review 1.  Ifosfamide in paediatric oncology: tried but not tested?

Authors:  P J Shaw; T Eden
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

Review 2.  Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects.

Authors:  M Cazzola; G Bergamaschi; L Dezza; P Arosio
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

3.  Acute ifosfamide-induced tubular toxicity.

Authors:  D Heney; I J Lewis; C C Bailey
Journal:  Lancet       Date:  1989-07-08       Impact factor: 79.321

4.  Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.

Authors:  M P Goren; C B Pratt; M J Viar
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Nephrotoxicity after ifosfamide.

Authors:  R Skinner; A D Pearson; L Price; M G Coulthard; A W Craft
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

6.  Urinary albumin excretion in school children.

Authors:  A G Davies; R J Postlethwaite; D A Price; J L Burn; C A Houlton; B A Fielding
Journal:  Arch Dis Child       Date:  1984-07       Impact factor: 3.791

7.  Increased carrying reduces infant crying: a randomized controlled trial.

Authors:  U A Hunziker; R G Barr
Journal:  Pediatrics       Date:  1986-05       Impact factor: 7.124

8.  Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease.

Authors:  C M Kunin; R W Chesney; W A Craig; A C England; C DeAngelis
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

9.  Parental counseling compared with elimination of cow's milk or soy milk protein for the treatment of infant colic syndrome: a randomized trial.

Authors:  B Taubman
Journal:  Pediatrics       Date:  1988-06       Impact factor: 7.124

10.  Analysis of proteinuria using a commercial system for automated electrophoresis and isoelectric focusing.

Authors:  P J Jackson; C J Sampson; E H Cooper; D Heney; J T Brocklebank
Journal:  Ann Clin Biochem       Date:  1988-05       Impact factor: 2.057

View more
  9 in total

Review 1.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Ifosfamide nephrotoxicity in paediatric cancer patients.

Authors:  M S Ashraf; J Brady; F Breatnach; P F Deasy; A O'Meara
Journal:  Eur J Pediatr       Date:  1994-02       Impact factor: 3.183

Review 3.  Ethical issues in including pediatric cancer patients in drug development trials.

Authors:  Katarina Aleksa; Gideon Koren
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats.

Authors:  N Chen; K Aleksa; C Woodland; M Rieder; G Koren
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

5.  Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide.

Authors:  J de Schepper; S Hachimi-Idrissi; O Louis; R Maurus; J Otten
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

Review 6.  Low molecular weight proteins in children with renal disease.

Authors:  P A Tomlinson
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714

Review 7.  N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.

Authors:  Hesamoddin Hosseinjani; Azadeh Moghaddas; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-19       Impact factor: 2.953

Review 8.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

9.  The influence of ifosfamide scheduling on acute nephrotoxicity in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.